The ongoing Mpox health emergency shines a light on the urgent need for effective therapeutics to prepare for and respond to endemic and pandemic diseases. That means: ✅ a healthy global therapeutics pipeline for endemic and pandemic diseases ✅ equitable access in low- and middle-income countries But how can we achieve this? #100DaysMission partners Shingai Machingaidze, Carmen Pérez Casas, Sheila Mburu, Ruxandra Draghia Akli, MD, PhD, Charles Mowbray, James Rosen, Esteban Burrone, Mona Nemer and Victor Dzau have set out their vision for a coalition to accelerate the discovery and development of therapeutics in PLOS: 🔸 https://lnkd.in/dXcpYpbk #Mpox #pandemicpreparedness #access2meds
Drugs for Neglected Diseases initiative - DNDi
Forschungsdienstleistungen
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.
Info
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.
- Website
-
https://dndi.org
Externer Link zu Drugs for Neglected Diseases initiative - DNDi
- Branche
- Forschungsdienstleistungen
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Geneva
- Art
- Nonprofit
- Gegründet
- 2003
- Spezialgebiete
- neglected diseases, drug development, leishmaniasis, human African trypanosomiasis, Chagas disease, malaria, filarial diseases, paediatric HIV, open innovation, not-for-profit, R&D, medicine, research, mycetoma, hepatitis C, dengue, ntds und neglected tropical diseases
Orte
Beschäftigte von Drugs for Neglected Diseases initiative - DNDi
-
Mae Shieh
Head, Business Development and Decarbonisation Project Lead at Drugs for Neglected Diseases initiative - DNDi
-
Herve Lecuelle
R&D Portfolio and Planning Head at DNDi
-
Joelle Tanguy
Health, Climate, Gender, Equity and Humanitarianism. Director @Drugs for Neglected Diseases initiative (DNDi) and Founder of Lyft Partners. Ex MSF |…
-
Delali A.
Global Executive Leader | Board Member & Advisor | Operator | Biopharma & Healthcare Expertise | Passionate @ People Access
Updates
-
📣 We're thrilled to announce that our Africa Ambassador Dr Monique Wasunna will be the keynote speaker as she kicks off this year's American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in New Orleans this November! Dr Wasunna has over 30 years of experience fighting on behalf of neglected patients, and has been a driving force in advancing healthcare solutions for neglected tropical diseases (NTDs) across Africa and beyond. As a pioneering researcher and passionate advocate for equitable access to health, her work has been instrumental in developing innovative therapies for neglected diseases like leishmaniasis. Her thought leadership in clinical research and her dedication to strengthening health systems have made a profound impact on global health, particularly in under-served communities. Congratulations to Dr Wasunna on this well deserved honour! 👏 🔸 Find out more about her work: https://lnkd.in/e4umJAjH #TropMed24 #NTDs #beatNTDs #access2meds #leishmaniasis
-
-
📢 Call for abstracts! The 6th Joint Scientific Meeting HAT Platform-EANETT will take place on 14-16 October 2024 in Conakry, Guinea 🇬🇳 The theme is 'Bringing innovation to contribute to the interruption of HAT transmission by 2030'. Submit your abstract by 15 September to contribute! 🔸 https://lnkd.in/deAgeE4j
-
-
The COVID-19 pandemic laid bare gross inequalities in access and affordability of life-saving health tools. Tests, treatments, and vaccines were produced at record speed, but people in lower-income countries struggled to secure access. We can't let this happen again. DNDi is working with our partners to help ensure that when (not if) the next pandemic hits, EVERYONE – including the poorest and most vulnerable communities – will have access to testing, treatment, and vaccine solutions they need. 🔗 Here's how: https://lnkd.in/dtqfT4Qv #covid19 #PandemicAgreement #PandemicPreparedness #HealthForAll
-
Today is World Mosquito Day. 🦟 ❓ But did you know... ❓ 🔸 Dengue is transmitted by the bite of the Aedes mosquito - and the species is rapidly spreading to new countries due to climate change. 🔸 Dengue is classified by the World Health Organization as a top 10 threat to global public health. 🔸 There are 390 million dengue infections per year - but no specific drugs available to treat the disease. Effective, affordable and accessible dengue treatments are urgently needed. That's why we're part of the Dengue Alliance 🤝, which brings together institutions from dengue-endemic countries to coordinate efforts to develop much-needed treatments. 🔗 Find out more about our work with dengue: https://lnkd.in/dK4FafFM #WorldMosquitoDay #dengue #DengueAlliance #InnovatingTogether
-
-
Liposomal amphotericin B (LAmB) is a game-changer for people with visceral leishmaniasis and AIDS-related cryptococcal meningitis, with fewer side effects and shorter hospital stays. But neglected populations can struggle to access this safer, more effective treatment. Despite high demand in low- and middle-income countries, patients face higher costs and limited supplier options. Janice Lee, Justine Odionyi, Rachel Cohen, Carol Ruffell (she/her), and Isabela Ribeiro have written about the urgent need for more LAmB suppliers to ensure equitable, affordable access for all. 📖 Read their paper in The Lancet Global Health: https://lnkd.in/dvRbzJev #leishmaniasis #cryptococcalmeningitis #AHD
-
-
Climate change disproportionately impacts the poorest and most marginalized communities. These same communities are hit hardest by neglected tropical diseases (NTDs) - which are on the rise due to changing weather patterns. We're delivering innovation and advocacy for the most neglected by: ✅ conducting much-needed research on climate-sensitive diseases such as dengue ✅ advocating for greater investment in R&D to enable climate adaptation and resilience ✅ taking concrete steps to reduce our own environmental impact To learn more about how we're advancing our response to the climate crisis, read our 2023 Annual Report: 📖 https://lnkd.in/dED-2ZM6 #climatechange #NTDs #dengue ##sleepingsickness #leishmaniasis #Chagas #mycetoma #riverblindness
-
'The world is at a crossroads, as climate change threatens to reverse hard-won progress on child health and the world becomes a more dangerous place for children.' UNICEF’s timely new report calls on all of us to protect children from the impacts of climate change. That means: ✅ prioritising child health and well-being in climate policy ✅ developing child-friendly medicines for climate-sensitive diseases The report highlights that nearly half of all children live in countries that are extremely vulnerable to the impacts of climate change. Only by addressing gaps in research and knowledge for diseases such as dengue can we make sure that safe, effective treatment will be available when children need it. 📖 Read the full report: https://lnkd.in/dc-mswDD #ClimateChange #dengue #malaria #BetterMeds4Kids #beatNTDs
-
-
Women are often excluded from clinical trials - meaning the resulting drugs aren't always safe for use during pregnancy or breastfeeding. Too many women have to delay much-needed treatment. We're committed to developing safe and effective treatments for women at ALL stages of life. 🔸 Find out more in our 2023 Annual Report: https://lnkd.in/e8GH98hb
-
-
To our partners, supporters, and staff who have walked with us through 20 years of innovating together - THANK YOU. 🙏 Together we can and will put equity at the heart of medical innovation in the years to come. 📖 Read the full foreword to our 2023 Annual Report: https://lnkd.in/e5nnxS6w #innovatingtogether
-